Tirzepatide and Mood: What the Clinical Evidence Actually Shows

What the prescribing information and NHS guidance say about mood

The Summary of Product Characteristics for tirzepatide, published on the electronic Medicines Compendium, lists mood-related effects in its safety profile. The NHS tirzepatide medicine page advises patients to contact a doctor or pharmacist if they notice any signs of depression or mood changes, and it is explicit that thoughts of self-harm or suicide warrant stopping the medicine and calling 111 or 999. That is the clearest signal in the official labelling: serious mood deterioration is not something to monitor quietly at home.

The SURMOUNT clinical programme, which involved thousands of adults across its trials, reported that psychiatric events including depressed mood and anxiety occurred in a minority of participants. The absolute rates were low, but regulators considered them significant enough to include in the product information. This matters because tirzepatide is a relatively new medicine still carrying the MHRA's Black Triangle designation, meaning any suspected effects should be reported. You can do that at the MHRA's Yellow Card scheme, and patients are actively encouraged to use it.

One practical checking habit that takes under a minute: at the end of each week, before your next injection, briefly rate your mood on a simple scale of one to ten in your phone's notes app. A gradual downward drift over several weeks is more informative than how you feel on any single day, and a clear pattern gives your prescriber something concrete to work with.

The indirect mood effects: nausea, sleep and appetite disruption

Mood does not change in isolation. Tirzepatide's most common side effects are gastrointestinal, and persistent nausea or disturbed sleep directly erodes emotional resilience. If you are eating very little, feeling queasy after meals, or waking at night, a dip in mood is a predictable human response rather than a pharmacological one. A fuller picture of these physical side effects is set out on our Mounjaro side effects page.

Appetite suppression also changes people's relationship with food in ways that can feel disorienting. Meals that used to be pleasurable become smaller or less appealing. For some this is straightforwardly welcome; for others, losing food as a source of comfort brings up feelings they did not expect. Research into GLP-1 medicines increasingly looks at these reward-pathway changes, and while the evidence is still emerging, it is a real experience that is worth naming. If this resonates, it is worth raising with your prescriber rather than assuming it will resolve on its own.

Dose increases tend to be the moments of highest GI burden, which means mood can temporarily dip at 5mg, 7.5mg and further up the schedule before settling again. Knowing this in advance helps you attribute a rough week correctly rather than concluding the medicine is wrong for you.

When weight loss improves mood: the positive side of the evidence

The full picture is not a cautionary one. A substantial body of evidence links meaningful weight reduction with improvements in depression scores, self-esteem, quality of life and energy. SURMOUNT-1, published in the New England Journal of Medicine, documented significant improvements in health-related quality of life alongside the weight outcomes, and participants reported feeling better physically and psychologically over the course of the 72-week trial.

For people whose weight has affected their confidence, mobility or social participation for years, the psychological lift that comes with noticeable change can be considerable. Prescribers generally see both sides: some patients feel meaningfully better within weeks; a smaller number find that mood worsens or that the changes in body image are more complicated than they anticipated. Neither response is unusual, and neither should be navigated alone. Our dedicated Mounjaro and mood page explores the positive evidence in more depth.

If you want to understand how tirzepatide compares to the broader treatment landscape before making a decision, the weight-loss treatment overview is a useful starting point.

Who should be especially careful, and when to act quickly

People with a current or recent diagnosis of depression, anxiety, bipolar disorder or another mood condition are not automatically excluded from tirzepatide treatment, but the prescriber needs to know. A thorough assessment is the only way to weigh up whether the potential benefits of treatment outweigh the risks for a specific person at a specific point in time. This is why every consultation at our pharmacy is reviewed personally by a GPhC-registered Independent Prescriber, not processed by an automated system.

Act quickly, not at your next scheduled check-in, if you notice: persistent low mood lasting more than a few days, a sense of emotional numbness, increasing anxiety, or any thoughts of self-harm. Stop the injection and contact your GP, call NHS 111, or in an emergency call 999. The Yellow Card scheme is also the right place to report any suspected psychiatric side effect, since it contributes to the ongoing monitoring of a medicine that is still accumulating real-world safety data.

For a broader look at the full side-effect profile, including gut-related effects like diarrhoea that can themselves affect mood, this page on tirzepatide and diarrhoea covers that particular experience in detail. And if what you have read here prompts questions about whether tirzepatide is right for you, our page covering how tirzepatide side effects can affect mood goes into further detail, while our guide to tirzepatide and mood swings is a useful companion if you are noticing more unpredictable emotional shifts, before starting a free consultation with our clinical team as the straightforward next step.